Central Nervous System Concentrations of Cyclooxygenase-2 Inhibitors in Humans
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Cyclooxygenase-2 (COX-2)-selective inhibitors (coxibs) are under investigation for the potential therapy, attenuation, or prevention of neuroinflammatory and neurodegenerative disorders. Coxibs are also a significant advance in pain therapy and are traditionally considered to achieve analgesia via peripheral effects. However, in animals, central nervous system (CNS) COX-2 activity and prostanoid concentrations are increased by peripheral inflammation, central sensitization has been proposed to account for long-term pain-related phenomena, and coxibs achieve significant cerebrospinal fluid (CSF) concentrations and may cause analgesia via CNS action. Nevertheless, it remains unknown whether or which coxibs reach the CNS in humans. This investigation determined whether coxibs can reach the CNS in humans, based on CSF concentrations. Methods: Ten healthy human volunteers simultaneously received a single oral dose of celecoxib (200 mg), rofecoxib (50 mg), and valdecoxib (40 mg). Blood and CSF were serially sampled for 10 h, and plasma total and unbound and CSF coxib concentrations were quantified by mass spectrometry. Results: Total plasma concentrations and time to maximum plasma concentration were similar among the three coxibs. In contrast, unbound (free) plasma concentrations differed significantly. Maximum unbound plasma concentrations were 1.4 +/- 0.5, 42 +/- 17, and 6.0 +/- 2.9 ng/ml, respectively, for celecoxib, rofecoxib, and valdecoxib. COX-2 inhibitors rapidly penetrated the CNS. Maximum CSF concentrations were 2 +/- 2, 57 +/- 25, and 10 +/- 4 ng/ml, respectively, for celecoxib, rofecoxib, and valdecoxib. CSF concentrations exceeding the median inhibitory concentration for COX-2 were achieved by rofecoxib and valdecoxib but not celecoxib. Conclusions: These results show that coxibs do reach the CNS in humans, with rapid penetration, and in concentrations apparently sufficient to inhibit COX-2 activity. There were significant differences among coxibs in CSF penetration. Unbound (free) plasma coxib concentration was the major determinant of CSF concentration. This supports the hypothesis that coxibs may act, in part, in the human CNS, provide important new information on the mechanism and treatment of pain and may guide coxib selection for therapeutic trials when CNS penetration is desirable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuronal plasticity: Increasing the gain in pain
Woolf, C. J., & Salter, M. W. (2000) · Science · doi:10.1126/science.288.5472.1765 · Cited by 3,781
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Cited by
Toward a Mechanism-Based Approach to Pain Diagnosis
Vardeh, D., Mannion, R. J., & Woolf, C. J. (2016) · The Journal of Pain · doi:10.1016/j.jpain.2016.03.001 · Cited by 319
Trial of celecoxib in amyotrophic lateral sclerosis
Cudkowicz, M. E., Shefner, J. M., Schoenfeld, D. A., Zhang, H., Andreasson, K. I., Rothstein, J. D., Drachman, D. B., & Northeast ALS Consortium (2006) · Annals of Neurology · doi:10.1002/ana.20903 · Cited by 301
Guo, J.-Y., Li, C.-Y., Ruan, Y.-P., Sun, M., Qi, X.-L., Zhao, B.-S., & Luo, F. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.076 · Cited by 148
“A previous clinical study shows that celecoxib does not reach COX2 inhibitory levels in human brain when given at a therapeutic dose (Dembo et al., 2005).”
BackgroundNrf2 participates in depressive disorders through an anti-inflammatory mechanism
Martín-de-Saavedra, M. D., Budni, J., Cunha, M. P., Gómez-Rangel, V., Lorrio, S., del Barrio, L., Lastres-Becker, I., Parada, E., Tordera, R. M., Rodrigues, A. L. S., et al. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.03.020 · Cited by 143
Telleria-Diaz, A., Schmidt, M., Kreusch, S., Neubert, A.-K., Schache, F., Vazquez, E., Vanegas, H., Schaible, H.-G., & Ebersberger, A. (2010) · Pain · doi:10.1016/j.pain.2009.08.013 · Cited by 109
Metadata
- Authors
- Dembo, G., Park, S. B., & Kharasch, E. D.
- Venue
- Anesthesiology
- Published
- 2005-02-01
- Volume
- 102
- Issue
- 2
- Pages
- 409-415
- ISSN
- 0003-3022 (ISSN-L)
- OpenAlex
- W2089485618
- Cited by
- 147
- References
- 2
- FWCI
- 8.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Central Nervous System Concentrations of Cyclooxygenase-2 Inhibitors in Humans. https://app.cochat.ai/papers/10.1097/00000542-200502000-00026
- The paper
- Dembo, G., Park, S. B., & Kharasch, E. D. (2005). Central Nervous System Concentrations of Cyclooxygenase-2 Inhibitors in Humans. Anesthesiology. https://doi.org/10.1097/00000542-200502000-00026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.